47,753 Medtronic PLC $MDT Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lessened its holdings in Medtronic PLC (NYSE:MDT – Free Report) by 6.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 664,017 shares of the medical technology company’s stock after selling 47,753 shares during the quarter. Voya Investment Management LLC’s holdings in Medtronic were worth $57,298,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. First Eagle Investment Management LLC grew its stake in shares of Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after purchasing an additional 3,739,288 shares during the last quarter. Cullen Capital Management LLC acquired a new stake in Medtronic in the second quarter valued at $202,764,000. State Street Corp raised its position in Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after purchasing an additional 1,658,301 shares during the last quarter. Amundi raised its position in Medtronic by 36.3% during the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after purchasing an additional 1,616,739 shares during the last quarter. Finally, Bank of America Corp DE raised its position in Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after purchasing an additional 1,343,220 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Latest Medtronic News

Here’s some of the latest news about MDT:

Insiders Place Their Bets

In other news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Marinaro sold 10,420 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. This trade represents a 8.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by company insiders.

Medtronic Stock Performance

Shares of MDT stock opened at $100.76 on Thursday. The company has a market cap of $128.89 billion, a price-to-earnings ratio of 24.82, a price-to-earnings-growth ratio of 2.39 and a beta of 0.56. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The firm has a 50 day moving average of $94.26 and a 200-day moving average of $88.48.

Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the previous year, the company earned $1.26 EPS. Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.98 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on MDT shares. TD Cowen set a $110.00 target price on Medtronic and gave the stock a “buy” rating in a report on Tuesday. Piper Sandler raised Medtronic from a “neutral” rating to an “overweight” rating and increased their price target for the company from $85.00 to $120.00 in a research note on Tuesday. Barclays upgraded Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a research note on Monday. Finally, UBS Group reaffirmed a “cautious” rating on shares of Medtronic in a research note on Wednesday, October 14th. Eighteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $103.75.

Read Our Latest Analysis on MDT

Medtronic Company Profile

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Articles

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.